Gordon C. McCauley
Gordon McCauley is a Partner of NDI Capital, which he co-founded in 2000.
From 2004 to 2013, Gordon was President & CEO of Allon Therapeutics Inc., a publicly traded biotech company. Under his leadership, Allon raised approximately $100 million in capital, took novel products from pre-clinical through to Phase III human clinical studies and was sold to Paladin Labs.
Gordon has held similar leadership roles in national healthcare service firms, as well as serving in a staff capacity for two Prime Ministers and former Ontario Premier David Peterson.
In addition to NDI, Gordon is a Director of BIOTECanada, LifeSciences British Columbia, Repurposed Therapeutics, The Centre for Drug Research and Development, and Hallmark Insurance where he serves as Chair. Until late 2013 Gordon was a Director of the Biotechnology Industry Organization (Bio), in Washington D.C., and served on the Executive Committee of its Emerging Companies Section.
Matthew J. Carlyle
Matthew Carlyle is a Partner of NDI Capital, which he helped to found in 2000.
From 2004 to 2013, Matthew was the Chief Financial Officer of Allon Therapeutics Inc., a publicly traded biotech company.
Previously, Matthew has served in Corporate Finance and Development roles for a number of public and private life-science and technology companies, and has been involved in raising approximately $200-mm.
Mr. Carlyle holds the Chartered Financial Analyst designation and is a member of the Association for Investment Management and Research, and the Vancouver Society of Financial Analysts.
James J. Miller, PhD
Dr. Miller, one of Canada’s most successful biotechnology entrepreneurs, was founding CEO of both QLT Inc. and Inex Pharmaceuticals.
In addition, as Senior Portfolio Manager for Trian Equities, he was instrumental in investing and providing strategic guidance to a variety of prominent biotechnology companies.
Dr. Miller co-founded NDI Capital in 2000.